---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016735"
form_type: "8-K"
ticker: "SRZN"
cik: "0001824893"
company_name: "Surrozen, Inc./DE"
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T01:04:44.962938+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "low"
source: SEC EDGAR
---

# Surrozen becomes clinical-stage with Phase 1 starts for SZN-1326 and SZN-043

## Summary
- Initiated Phase 1 trial for SZN-1326 (ulcerative colitis) in May 2022 and for SZN-043 (alcoholic hepatitis) in June 2022.
- Presented preclinical data for SZN-413 (diabetic retinopathy) at ARVO and for other pipeline programs at Digestive Disease Week.
- Q2 2022 financial results reported but specific figures (revenue, EPS, net loss) not included in provided exhibit text.
- Company noted no treatment-related adverse effects in preclinical toxicology studies for both lead candidates.

## SEC filing metadata
- accession: 0000950170-22-016735
- form_type: 8-K
- ticker: SRZN
- cik: 0001824893
- company_name: Surrozen, Inc./DE
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: low
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824893/000095017022016735/0000950170-22-016735-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824893/000095017022016735/srzn-20220811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016735
- JSON: https://secwatch.observer/filing/0000950170-22-016735.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016735.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.